Cyclacel Pharma (CYCC) Misses Q4 EPS by 45c

Cyclacel Pharma (NASDAQ: CYCC) reported Q4 EPS of ($1.18), $0.45 worse than the analyst estimate of ($0.73). Revenue for the quarter came in at $277 thousand versus the consensus estimate of $210 thousand.

For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.

You May Also Be Interested In

• Kura Sushi (KRUS) Tops Q3 EPS by 3c; offers outlook
• Penguin Solutions (PENG) Tops Q2 EPS by 28c, Beats on Revenue; Offers FY26 EPS Guidance
• HSBC Reiterates Buy Rating on Samsung Electronics Co Ltd. (005930:KS) (SSNLF)